Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Recruiting · NCT05849857 · Registry updated 2023-11-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2023-11-01 | NCT05849857 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aarhus University Hospital | 297 |
| Hoffmann-La Roche | 280 |
| Oslo University Hospital | 327 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Helsinki University Hospital | Helsinki | Finland | 46 |
| Oslo University Hospital | Oslo | Norway | 37 |
| St. Olavs hospital | Trondheim | Norway | 17 |